Olmutinib

Olmutinib
Clinical data
Other namesHM-61713, BI-1482694
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • Approved in South Korea
Identifiers
IUPAC name
  • N-{3-[(2-{[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC26H26N6O2S
Molar mass486.59 g·mol−1
3D model (JSmol)
SMILES
  • CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C
InChI
  • InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
  • Key:FDMQDKQUTRLUBU-UHFFFAOYSA-N

Olmutinib (INN)[1] is an investigational anti-cancer drug. It acts by covalently bonding to a cysteine residue near the kinase domain of epidermal growth factor receptor (EGFR).[2]

In the US, it was given a breakthrough therapy designation in non-small cell lung cancer (NSCLC) in December 2015, and In South Korea, the drug was approved in May 2016 for the second-line treatment of NSCLC with the T790M mutation of EGFR.[2] Resistance to olmutinib has been reported; a person's cancer started progressing after they developed a C797S mutation in EGFR.[2][3]

Olmutinib was discovered by Hanmi Pharmaceutical and licensed to Boehringer Ingelheim in 2015 in an agreement with a $50 million up front payment and up $680 million in milestones.[4] In November 2015 Hanmi granted an exclusive license to sell olmutinib in China to the Chinese company ZAI Labs.[5]

On September 30, 2016, Korean regulatory authorities issued a safety alert about olmutinib in which it described two cases of toxic epidermal necrolysis, one of which was fatal, and a case of Stevens–Johnson syndrome; Boeheringer announced the termination its deal with Hanmi the same day, citing that the decision came after a review of "all available clinical data" on the drug, and also referring to competing drugs.[6]

References

  1. ↑ "Olmutinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 February 2017.
  2. 1 2 3 Liao BC, Lin CC, Lee JH, Yang JC (December 2016). "Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors". Journal of Biomedical Science. 23 (1): 86. doi:10.1186/s12929-016-0305-9. PMC 5135794. PMID 27912760.
  3. ↑ Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, et al. (March 2017). "Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment". Pharmacological Research. 117: 406–415. doi:10.1016/j.phrs.2017.01.003. PMID 28089942. S2CID 45855336.
  4. ↑ Garde D (July 29, 2015). "Boehringer bets up to $730M on a new lung cancer drug". FierceBiotech.
  5. ↑ Keenan J (April 14, 2016). "South Korea's Hanmi to spend $200M in China expansion". FiercePharma.
  6. ↑ Carroll J (October 1, 2016). "Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal". Endpoints.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.